MammaPrint

MAMMAPRINT: A TEST TO PREDICT RISK OF BREAST CANCER RECURRENCE

MammaPrint analyzes the 70 most important genes associated with breast cancer recurrence to classify each breast cancer patient into “Low Risk” or “High Risk” of developing metastases within the first 10 years after diagnosis—without the ambiguity associated with “intermediate” scores found in some other tests.

The clarity that MammaPrint delivers helps patients and physicians make informed, confident treatment management decisions.

MammaPrint is FDA-cleared (US) for women of all ages. The device is also CE marked allowing for use in the European Union.

The test is validated by peer-reviewed data and supported by the highest level of clinical evidence from a landmark randomized,* prospective,† phase III‡ clinical trial known as MINDACT.

Over 75,000 women have chosen MammaPrint to help provide greater clarity on their risk of breast cancer recurrence.
Of physicians had complete or high confidence in their treatment recommendations after receiving the MammaPrint test result, compared to 69% pre-test.2

  • I see MammaPrint as a great tool which helps you to navigate through difficult decisions.

    Andrea, a breast cancer survivor

  • I was very reassured after receiving my low risk score! Having the MammaPrint test put my mind at ease.

    Stephany, a breast cancer survivor

  • I called Agendia about my financials, and the person I spoke to was great. She answered all my questions, explained the process, and told me what the steps were.

    Angie, a breast cancer survivor

  • I am so thankful that I had all the information I needed—thanks to personalized medicine—to make the right decision for me and my particular cancer. I was treated as an individual and not as a disease.

    Sara, a breast cancer survivor

  • I kept thinking maybe I’d made the wrong decision, maybe I should have had a mastectomy. MammaPrint allowed me to calm down, refer back to my results, and return to the faith I had in my treatment.

    Mary, a breast cancer survivor

Recommended by expert medical guidelines

MammaPrint is included in numerous clinical practice guidelines developed by world-recognized cancer care organizations. Clinical guidelines are evidence-based recommendations for healthcare professionals involved in the management of patients.

Guidelines aim to improve the quality of care and services based on the most up to date peer-reviewed evidence. For example, MammaPrint is the only test of its kind endorsed by the American Society of Clinical Oncology for lymph node-positive patients.

*Randomization is a procedure to allocate clinical study participants into different groups. By using chance to allocate participants, the groups are likely to be similar and allow the effects of the treatments to be compared more fairly.

 

†When patients are recruited to a clinical study and followed forward in time.

 

‡A type of clinical trial designed to confirm and expand on the safety and/or effectiveness of an intervention from earlier clinical trials. Phase III trials are often large and may consist of hundreds or even thousands of patients.

 

REFERENCE

 

1 Cardosa F, van’t Veer LJ, Bogaerts J et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med 2016; 375: 717-29.

 

2 Wuerstlein R, et al. Results of multigene assay (MammaPrint®) and molecular subtyping (BluePrint®) substantially impact treatment decision making in early breast cancer: Final analysis of the WSG PRIMe Decision Impact Study. Poster presented at San Antonio Breast Cancer Symposium. December 2016; San Antonio, Texas